These are top 10 stocks traded on the Robinhood UK platform in July
DUBLIN and BRIDGEWATER, N.J. - Amarin Corporation plc (NASDAQ:AMRN) announced today that it will present new in vitro data on its cardiovascular drug at the upcoming American College of Cardiology Annual Scientific Session & Expo later this month in Chicago. The data focus on the mechanistic activities of eicosapentaenoic acid (EPA), the active ingredient in Amarin’s icosapent ethyl product, VASCEPA/VAZKEPA, which is used to reduce cardiovascular events in at-risk patients.
Steve Ketchum, EVP, President of R&D and Chief Scientific Officer at Amarin, highlighted the significance of the research in understanding the potential benefits of combining EPA with other therapies, such as GLP-1 receptor agonists, known to reduce cardiovascular risk alongside LDL-C lowering statin therapy.
The research to be presented includes findings on the antioxidant effects of EPA on lipoprotein(a)-enriched plasma and the effects of combining a GLP-1 receptor agonist with EPA on the expression of antioxidant proteins in endothelial cells during inflammation. These studies have been supported by Amarin and will be featured in moderated poster presentations at the ACC expo.
Amarin is known for its focus on addressing cardiovascular risk that persists beyond traditional therapies. VASCEPA, launched in the United States in January 2020, is the first FDA-approved prescription treatment comprised solely of icosapent ethyl for patients with elevated triglyceride levels who are already on statin therapy. Despite advances in controlling LDL-C, cardiovascular disease remains the leading cause of death, with significant risk persisting even after statin therapy, particularly in patients with elevated triglycerides.
The company emphasizes that this press release contains forward-looking statements, which involve risks and uncertainties, and reminds investors not to place undue reliance on these statements. The data and information presented are based on a press release statement and are intended to contribute to the scientific dialogue at the ACC Annual Scientific Session & Expo from March 29-31, 2025.
In other recent news, Amarin Corporation reported its fourth-quarter 2024 earnings, showcasing a better-than-expected performance in terms of earnings per share (EPS), which came in at -0.02 against a forecast of -0.05. However, the company experienced a decline in total net revenue, which fell to $62.3 million from $74.7 million in the same quarter of the previous year. Despite the positive EPS result, the decline in U.S. product revenue contributed to the overall financial performance challenges. Amarin’s total revenue for 2024 was $228.6 million, with U.S. product revenue specifically decreasing to $44.2 million from $64.9 million year-over-year. On a more positive note, European product revenue increased to $4 million, and partnership revenue rose by $7.7 million to $11.9 million.
In terms of market opportunities, Amarin extended its patent protection for Vascepa in Europe to 2039, which may secure future market opportunities. The company maintains a strong cash position with $294 million and no debt. Analysts from firms like JPMorgan and Leerink have shown interest in Amarin’s financial strategies and potential pipeline expansion. Despite the mixed financial results, Amarin aims to maintain its NASDAQ listing and drive momentum in European and global markets.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.